COVID-19 Alert: Increased risk of drug-related overdoses. Due to State of Emergency, please go to nearest Bridge Clinic to obtain Naloxone or if in treatment, ask your behavioral health provider. If you are unable to leave your home, please contact mobile crisis at 1-800-652-2929.
Safe Prescribing Reduces Risk and Can Improve Outcomes.
Improving the Way Opioids Are Prescribed Benefits Everyone.
Clinical practice guidelines, the Prescription Monitoring Program, MME calculators, and tools to help assess patients’ pain and risk for addiction are assets prescribers can use to help guide opioid prescribing. Monitoring, tapering use, and being aware of alternative approaches to manage pain, and of a patient’s potential for abuse, can improve a patient’s pain outcome and reduce the risk of addiction.
Guidelines for Prescribing Opioids Establish a Clear Decision-Making Process.
The Centers for Disease Control and Prevention (CDC) has established specific guidelines for safely prescribing opioids, which include the following key recommendations:
- Opioids are not the first-line or routine therapy for chronic pain.
- Establish and measure goals for pain and function.
- Discuss benefits, risks, and availability of non-opioid therapies with patient.
- Use immediate-release opioids when starting.
- Start low and go slow.
- When opioids are needed for acute pain, prescribe no more than what’s needed.
- Do not prescribe ER/LA opioids for acute pain.
- Follow up and re-evaluate risk of harm; reduce dose or taper and discontinue if needed.
- Evaluate risk factors for opioid-related harms.
- Check PMP for high dosages and prescriptions from other providers.
- Use urine drug testing to identify prescribed substances and undisclosed use.
- Avoid concurrent benzodiazepine and opioid prescribing.
- Arrange treatment for Opioid Use Disorder if needed.
Refer to the CDC’s guide for prescribers to understand when opioids should be considered; what to do before starting opioid treatment for chronic pain; how to select opioid dosage, duration, follow-up, and discontinuation; and how to assess risks and harms.
Evaluate the benefits and harms with patients before initiating — and during — opioid therapy. Benefits and harms should be evaluated every three months, or more frequently.
Use Proven Tools to Assess Pain and Risk.
There are many ways pain affects your patients’ lives. The Pain, Enjoyment, and General Activity (PEG) evaluation can give you a simple, basic measurement of what they’re dealing with to help you determine the best therapy. But how can you determine if a patient could be a risk candidate in the future? Here are additional tools to help you use quantifiable measures to help determine the patient’s risk for substance abuse and addiction.
Assess your patients’ pain and function using the three-question PEG scale. Evaluating the level of pain and interference with the enjoyment of life and general activity on a scale of zero to 10 helps clarify the need for opioid therapy for chronic pain.
Assess your patients’ risk using the Opioid Risk Tool, which helps you learn your patients’ family and personal history of substance use/abuse, sexual abuse, and psychological disease.
Complete the informed consent and treatment agreements, to ensure that your patient is aware of the risks of opioid therapy.
Alternative Therapies Can Be as Effective as Opioids for Pain Management.
A growing body of literature supports the conclusion that non-opioid approaches to managing pain can be more effective, with less risk. For example, a study published in the March 2018 Journal of American Medicine looked at whether opioid pain medications are more effective than non-opioid medications in treating chronic pain. The study examined 240 patients with moderate to severe chronic back pain or hip or knee osteoarthritis pain. One group of patients was given opioid pain medications. In a second group, patients were given non-opioid pain medications. Researchers found that after 12 months of treatment, the patients who took the opioid pain medication were not functioning any better than those who treated their pain with the non-opioid pain relievers.
- Opioids should not be the first line of treatment for chronic pain.
- Non-opioid medications can be effective for treatment of chronic pain.
Patients with pain should receive treatment that provides the greatest benefit. Opioids are not the first-line choice of therapy for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Evidence suggests that non-opioid treatments, including non-opioid medications and nonpharmacological therapies, can provide relief to those suffering from chronic pain, and are safer. Effective approaches to chronic pain include non-opioid medications and nonpharmacological treatments.
Naloxone Can Benefit Your Patients Who Are Prescribed High-Risk Medications.
Naloxone can prevent an opioid overdose death by blocking receptor sites and reversing the toxic effects of the overdose. Prescribers should consider incorporating strategies to mitigate risk for overdose, including offering naloxone to all patients who are prescribed opioids. Use the concept of “risky medicines,” instead of “risky patients,” to frame your discussions and engage in proactive dialogue to minimize poisoning, over-sedation, and overdose risk with patients who need opioid medications to improve function. Discussing an emergency overdose/poisoning/over-sedation plan and possibly prescribing naloxone is an essential component of that dialogue.
Naloxone (also known as Narcan):
- Is a highly specific, high-affinity opioid antagonist used to reverse the effects of opioids.
- Can be safely administered by the average person via intramuscular or intranasal routes with virtually no side effects and no effect in the absence of opioids.
- The effects last 30 to 90 minutes — usually sufficient for short-acting opioids, but emergency assistance should always be sought.
- While high doses of intravenous naloxone by paramedics have been associated with withdrawal symptoms, lower lay-administered doses produce much milder effects.
According to the CDC, the AMA Task Force to Reduce Opioid Abuse and other authorities, patients considered at risk for opioid overdose are those who:
- Have a history of overdose or sedation
- Have a history of alcohol or other substance use disorder
- Engage in active illicit drug use
- Are taking high daily doses of opioids (≥50 MME/day)
- Switch from one opioid to another
- Take opioids for pain and have respiratory problems
- Take opioids for pain and have renal/liver disease or other conditions such as hepatic disease, cardiac illness or HIV/AIDS
- Take opioids and smoke, have COPD, emphysema, asthma, sleep apnea, respiratory infection, or other respiratory conditions
- Are concurrently taking opioids and benzodiazepine or other sedatives
- Are taking opioids and antidepressants
- Are taking opioids and have an underlying mental health condition
- Have a high-risk score per the PMP
Before prescribing naloxone, determine the patient’s overdose risk and obtain and patient history:
- Review medications
- Take a substance use history
- Check the PMP
- Take an overdose history — ask your patient whether he or she has:
- Overdosed or had a bad reaction to taking opioid medications
- Witnessed an overdose
- Received training to prevent, recognize, or respond to an overdose
You may also consider prescribing naloxone for at-risk patients:
- Who may have difficulty accessing emergency medical services (distance, remoteness)
- When the patient or caregiver has requested it
Two naloxone formulations are available:
Intramuscular (IM) injection and Intranasal (IN) spray are each available in two different forms.
|Intra-nasal||Intra-nasal released in 2016||Intra-muscular||Auto-Intra-Muscular|
|Naloxone 1mg/1mL||Naloxone (4mg/0.1 mL)||Naloxone (0.4mg/1 mL)||Naloxone (0.4mg/1 mL)|
|Two 2 mL prefilled Luer-JetTM Luer-Lock needleless syringe PLUS 2 mucosal atomizer devices (MAD-300)||#1 two pack||Two single-use 1 mL vials||#1 two pack|
Sig released in 2016
|Spray 1 mL (half of the syringe) into each nostril. Repeat after 2-3 minutes if no or minimal response.||Spray full dose into one nostril. Repeat into other nostril after 2-3 minutes if no or minimal response.||Inject 1 mL in shoulder or thigh. Repeat after 2-3 minutes if no or minimal response.||Use as directed by voice-prompt. Press black side firmly on outer thigh. Repeat after 2-3 minutes if no or minimal response.|
Patient instructions and counseling:
- Instruct patients to administer if non-responsive from opioid use, and on how to assemble the naloxone injection or spray so that it can be administered.
- Include family and caregivers in patient counseling or instruct the patient to train others.
Higher Dosages — and Co-Prescribing — Are Associated with Higher Risk.
Understanding dosage thresholds reduces the risk of harm to the patient. Calculating dosage can be complicated. Converting to morphine milligram equivalents (MME) helps to identify which patients are at increased risk. For example, patients who take dosages at or above 50 MME per day have twice the risk of overdose than those who take less. Calculations of MME are automatically figured by the PMP, based on data reported (prescriptions filled at pharmacies).
Co-prescribing opioids with other medications, especially benzodiazepines, can significantly increase the risk of overdose. According to the National Institute on Drug Abuse , more than 30 percent of overdoses involving opioids also involve benzodiazepines. Combining opioids and benzodiazepines can be unsafe since both types of drug sedate users and suppress breathing — the cause of overdose fatality — in addition to impairing cognitive functions.
A Urine Drug Screening Can Establish and Monitor Patient Risk.
Urine drug testing can identify drug use that is not reported by your patients. Have an open conversation with your patient about urine testing so that they understand what the test may show, and explain that this is to help protect them and keep them safe from harm.
Tapering and Discontinuing Opioid Therapy Should Be the Ultimate Goal.
There are specific circumstances when you should consider tapering or discontinuing a patient’s opioid therapy. Those circumstances usually involve patients who:
- Aren’t seeing any meaningful improvement
- Request a dosage reduction
- Are taking dosages of 50 MME per day or higher without benefit, or are combining opioids with benzodiazepines
- Are exhibiting signs of substance use disorder
- Have overdosed or had another adverse event
- Show warning signs of an overdose risk, such as slurred speech, sedation, or confusion
Safely Disposing of Unused Opioids Protects Us — and the Environment.
Of people who abuse prescription pain relievers, 70 percent get them from friends and relatives. To avoid having unused drugs fall into the hands of people for whom they were not prescribed, refer to the following recommendations to dispose of unused drugs with care.
Educate Your Patients About Opioid Use and Risks.
You may be considering opioids to help your patients manage chronic pain. Prescription opioids are often used to help relieve moderate to severe pain following a surgery or an injury, or for certain health conditions. These medications can be an important part of treatment, but also come with serious risks. A fully informed patient is a better patient. Information can set expectations and make patients aware of the risks involved.
Prescription opioids carry serious risks for addiction and overdose, especially with prolonged use. An opioid overdose, often marked by slowed breathing, can cause sudden death. The use of prescription opioids can have a number of side effects as well, even when taken as directed:
- Tolerance, meaning you might need to take more of a medication for the same pain relief
- Physical dependence, meaning you have symptoms of withdrawal when a medication is stopped
- Increased sensitivity to pain
- Nausea, vomiting, and dry mouth
- Sleepiness and dizziness
- Low levels of testosterone that can result in lower sex drive, energy, and strength
- Itching and sweating
Risks are greater with:
- History of drug misuse, substance use disorder, or overdose
- Mental health conditions (such as depression or anxiety)
- Sleep apnea
- Older age (65 or older)
- Drug overdose is the leading cause of accidental death in the United States.
- Opioid addiction is driving the drug epidemic.
- Opioids come with serious risk for addiction, abuse, and overdose.
- Other pain management options may actually work better and have fewer risks and side effects:
- Acetaminophen (Tylenol®) or ibuprofen (Advil®)
- Cognitive behavioral therapy — a psychological, goal-directed approach in which patients learn how to modify physical, behavioral, and emotional triggers of pain and stress
- Exercise therapy, including physical therapy
- Medications for depression or seizures
- Interventional therapies (injections)
- Exercise and weight loss
- Other therapies such as acupuncture and massage